Trifluoperazine is a phenothiazine used to treat depression, anxiety, and agitation. A phenothiazine with actions similar to chlorpromazine.
- Mechanism
- Curator reviewed
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
- Primary indication
- For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.Curator reviewed · 4 structured indications
- Formula / weight
- C21H24F3N3S · 407.496 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1981
- Also known as
- Trifluoroperazine · Trifluperazine
- Code names
- NSC-17474 · RP-7623
Resolves to
Clinical / RWD
Structure
InChIKey
ZEWQUBUPAILYHI-UHFFFAOYSA-NSMILESCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1Targets
Transporters
What you can answer from here — as of September 13, 2026
11Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Trifluoperazine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account